Sign in to view content

ENVISION Trial 24-Week Data: Phase 2 Study of UBX1325, a New Senolytic Agent for Patients With Wet AMD

Raj K. Maturi, MD

Video
Published 2023

Related

Treatment course and outcomes of neovascular age-related macular degeneration in patients receiving intraocular pressure-lowering drops
Bobeck S Modjtahedi, MD
On Demand Cases, Courses, and Papers
2019
Two-Year Results From the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of Neovascular AMD
Robert L. Avery, MD
Updates from the Field
2021
OCT Angiography (OCTA) and Exudative Age-Related Macular Degeneration (ARMD)
Mark H. Nelson, MD, MBA
Updates from the Field
2017

Category: AMD-Neovascular

See more